Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will host its fourth quarter and year-end 2025 financial results conference call and webcast on February 11, 2026. The press release will be issued at 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET. Domestic dial-in: 800-579-2543; international dial-in: 785-424-1789; conference ID: NBIX. The webcast will be available at neurocrine.com under Investors, with a replay posted about one hour after the event and archived for ~one month.

Neurocrine focuses on treatments for neurological, psychiatric, endocrine and immunological disorders and maintains a mid-to-late phase clinical pipeline.

News Market Reaction – NBIX

+1.45%

1 alert

+1.45% News Effect

On the day this news was published, NBIX gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4/YE 2025 press release time: 1:00 p.m. PT / 4:00 p.m. ET Q4/YE 2025 call time: 1:30 p.m. PT / 4:30 p.m. ET Domestic dial-in: 800-579-2543 +4 more

7 metrics

Q4/YE 2025 press release time 1:00 p.m. PT / 4:00 p.m. ET Scheduled on February 11, 2026

Q4/YE 2025 call time 1:30 p.m. PT / 4:30 p.m. ET Earnings conference call on February 11, 2026

Domestic dial-in 800-579-2543 U.S. access number for earnings call

International dial-in 785-424-1789 International access number for earnings call

Conference ID NBIX Identifier for February 11, 2026 earnings call

Webcast replay window Approximately one month Replay archived on investor website

Company history Three decades Duration of Neurocrine’s neuroscience focus

Market Reality Check

Price: $128.63 Vol: Volume 1,055,884 is sligh...

normal vol

$128.63 Last Close

Volume Volume 1,055,884 is slightly below the 20-day average of 1,094,987 (relative volume 0.96). normal

Technical Price 134.54 is trading modestly above the 200-day MA at 132.32.

Peers on Argus

NBIX is up 1.62% with modest volume while key peers show mixed but generally pos...

NBIX is up 1.62% with modest volume while key peers show mixed but generally positive moves (e.g., TEVA +1.9%, UTHR +1.54%, TAK +1.51%, RDY +0.47%, VTRS -0.67%). Momentum scanner does not flag a coordinated sector move.

Historical Context

5 past events · Latest: Jan 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Head-to-head data	Positive	-1.5%	INGREZZA showed higher VMAT2 occupancy vs AUSTEDO XR with good tolerability.
Jan 05	Conference presentation	Positive	+1.0%	Participation in J.P. Morgan Healthcare Conference highlighted company and portfolio.
Dec 22	Phase 3 trial update	Negative	-0.2%	Valbenazine failed to meet primary and key secondary endpoints in DCP.
Dec 16	R&D Day strategy	Positive	-4.7%	R&D Day outlined transformed strategy and multiple future clinical milestones.
Dec 09	R&D Day notice	Neutral	+0.4%	Announcement of upcoming 2025 R&D Day webcast and agenda details.

Pattern Detected

NBIX has occasionally sold off on positive R&D news (e.g., R&D Day and favorable INGREZZA data), while negative clinical outcomes and routine event notices have seen relatively muted or aligned price reactions.

Recent Company History

Over the past several months, NBIX has reported mixed but generally active news flow. A Phase 3 valbenazine study in dyskinetic cerebral palsy failed primary and key secondary endpoints on Dec. 22, 2025, with only a small negative reaction. The 2025 R&D Day on Dec. 16 highlighted an ambitious pipeline, yet shares fell 4.73%. By contrast, investor‑relations events such as the J.P. Morgan Healthcare Conference and prior R&D Day announcements saw mild positive moves. Today’s Q4 and year‑end 2025 call scheduling fits this pattern of routine earnings communications.

Market Pulse Summary

This announcement sets the timetable for NBIX’s Q4 and year‑end 2025 financial results, with the pre...

Analysis

This announcement sets the timetable for NBIX’s Q4 and year‑end 2025 financial results, with the press release at 1:00 p.m. PT and the call at 1:30 p.m. PT on February 11, 2026. Historically, similar quarterly scheduling notices have produced modest price moves. Investors may focus more on prior clinical updates, R&D strategy, insider activity, and recent ownership disclosures when framing expectations for the upcoming financial discussion.

Key Terms

tardive dyskinesia, chorea, Huntington's disease, classic congenital adrenal hyperplasia, +3 more

7 terms

tardive dyskinesia medical

"FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

chorea medical

"FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease"

Chorea is a neurological condition that causes sudden, irregular, involuntary movements—like fragments of a dance you can’t control—that can affect the face, limbs, or trunk. It matters to investors because chorea can drive demand for treatments, influence clinical trial design and regulatory decisions, and signal safety or liability risks for companies developing therapies or diagnostics, all of which affect potential market size and financial outlooks.

Huntington's disease medical

"treatments for tardive dyskinesia, chorea associated with Huntington's disease"

A hereditary brain disorder caused by a faulty gene that progressively damages nerve cells, leading to uncontrollable movements, thinking and mood problems, and a shortened lifespan. It matters to investors because the disease creates a clear medical need and potential market for treatments, so news about clinical trial results, regulatory progress, or drug approvals can strongly move biotech and pharmaceutical stock values. Think of it as a predictable, inherited mechanical flaw in a complex machine that companies are trying to fix.

classic congenital adrenal hyperplasia medical

"treatments for tardive dyskinesia, chorea ... classic congenital adrenal hyperplasia"

A genetic disorder present at birth in which the adrenal glands cannot make the right balance of hormones, usually because a key enzyme is missing, leading to low stress and salt-regulating hormones and excess sex hormones; it can cause dehydration and abnormal genital development in newborns. Investors care because the condition requires lifelong management, newborn screening and specialized drugs or tests, so advances in therapies, diagnostics or gene treatments can create durable markets and regulatory milestones.

endometriosis medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"endometriosis* and uterine fibroids*, as well as a robust pipeline"

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

biopharmaceutical medical

"Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

AI-generated analysis. Not financial advice.

Conference Call and Webcast Scheduled for Wednesday, February 11

SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026.

The schedule for the press release and conference call / webcast is as follows:

• Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
  
  
• Q4 and Year-End 2025 Conference Call: February 11, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
  
  
• Domestic Dial-In Number: 800-579-2543
  
  
• International Dial-In Number: 785-424-1789
  
  
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2025-financial-results-302667190.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) report Q4 and year-end 2025 results?

The press release will be issued on February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ET.

What time is the NBIX conference call and webcast on February 11, 2026?

The conference call and webcast start at 1:30 p.m. PT / 4:30 p.m. ET on February 11, 2026.

How can investors access the Neurocrine (NBIX) webcast replay?

A replay will be available approximately one hour after the event and archived for about one month on neurocrine.com under Investors.

What are the dial-in details for Neurocrine (NBIX) Q4 2025 earnings call?

Domestic dial-in: 800-579-2543; international dial-in: 785-424-1789; Conference ID: NBIX.

Will Neurocrine (NBIX) provide slides or multimedia for the February 11, 2026 webcast?

The company notes the webcast is accessible via its website and multimedia may be available for download on the investor site.